Reply to the short sellers

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
sargasso
Posts: 107
Joined: Fri Mar 11, 2016 8:49 pm

Reply to the short sellers

Post by sargasso » Mon Apr 09, 2018 5:16 pm

“In fact, one of the most comprehensive studies on the matter published just last month in Annals of Hematology by Kuykendall et al. reported a median overall survival in patients that discontinue Incyte's Jakafi of only 13 months. So stating that imetelstat's projected median overall survival of 22 to 24 months is somehow not clinically meaningful in patients headed toward bone marrow failure is completely out of step with the peer-reviewed literature.” Two links below:

First link is the article by George which in my opinion is very good:

https://finance.yahoo.com/news/3-reason ... 00532.html

Second link:

Abstract of article cited by George:

https://link.springer.com/article/10.10 ... 017-3194-4

Dogonenuts
Posts: 40
Joined: Tue May 10, 2016 6:13 pm

Re: Reply to the short sellers

Post by Dogonenuts » Mon Apr 09, 2018 8:59 pm

More and more I feel we will see Imet as first line Tx, as discontinuation rate of Jakafi is pretty high.

Post Reply